RT Book, Section A1 Kurokawa, Yukinori A1 Doki, Yuichiro A2 Morita, Shane Y. A2 Balch, Charles M. A2 Klimberg, V. Suzanne A2 Pawlik, Timothy M. A2 Posner, Mitchell C. A2 Tanabe, Kenneth K. SR Print(0) ID 1145761389 T1 Surgical and Multimodality Treatments of Cancers at the Esophagogastric Junction: The Eastern Perspective T2 Textbook of Complex General Surgical Oncology YR 2018 FD 2018 PB McGraw-Hill Education PP New York, NY SN 9780071793315 LK accesssurgery.mhmedical.com/content.aspx?aid=1145761389 RD 2024/03/28 AB The incidence of gastric adenocarcinoma in the East is much higher than in the West; the main etiology is Helicobacter pylori (H. pylori) infection. However, in Japan esophageal adenocarcinoma accounts for only 4.3% of all cases of esophageal cancer, which is a rather low proportion compared to the West.1 Although the high prevalence of H. pylori infection has contributed to a decrease in the risk of esophageal adenocarcinoma in the East, decreased prevalence of H. pylori infection and increased incidence of obesity have gradually increased the incidence of esophagogastric junction (EGJ) cancer in recent years.2 Treatment for EGJ cancer requires special attention to surgical technique, in particular to lymph node dissection. Although surgery is the most effective curative treatment for EGJ cancer, the proportion of R1 or R2 resections is comparatively high. Even after R0 resection, the recurrence rate is high. To improve the R0 resection rate and long-term outcomes, perioperative treatment has been attempted. In this section, we outline the Eastern perspective on the surgical approach and perioperative therapy for EGJ cancer.